Population pharmacokinetics of orvacabtagene autoleucel, an autologous BCMA-directed chimeric antigen receptor T-cell product, in patients with relapsed/refractory multiple myeloma

This article looked at a study of orvacabtagene autoleucel (orva-cel), a CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. A modified model better characterized orva-cel pharmacokinetics than traditional models by incorporating a cell number-dependent expansion rate. Dose level, plasma cell percentage in bone marrow, and anti-therapeutic antibodies were significant covariates impacting expansion and persistence